ScholarIQanswers from OpenAlex & ORCID
Steven A. Feldman
ResearcherPublications, citations & collaboration network
Steven A. Feldman is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Steven A. Feldman have?
ScholarIQindexed works
Steven A. Feldman has 254 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Steven A. Feldman have?
ScholarIQcitation count
Steven A. Feldman has 24,934 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Steven A. Feldman?
ScholarIQh-index
Steven A. Feldman has an h-index of 52 in OpenAlex.
What is the i10-index of Steven A. Feldman?
ScholarIQi10-index
Steven A. Feldman has an i10-index of 89 in OpenAlex.
What is the ORCID of Steven A. Feldman?
ScholarIQorcid
The ORCID for Steven A. Feldman is on the source record.
What is the OpenAlex record for Steven A. Feldman?
ScholarIQopenalex
The OpenAlex for Steven A. Feldman is on the source record.
What are the most-cited papers on Steven A. Feldman?
ScholarIQmost cited works
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson, Yongzhi Cui, Cindy Delbrook, Steven A. Feldman, Terry J. Fry, Rimas J. Orentas, Marianna Sabatino, Nirali N. Shah, Seth M. Steinberg, D. Stroncek, Nick Tschernia, Constance M. Yuan, Hua Zhang, Ling Zhang, Steven A. Rosenberg, Alan S. Wayne, Crystal L. Mackall
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins, Richard A. Morgan, Steven A. Feldman, James C. Yang, Richard M. Sherry, Mark E. Dudley, John R. Wunderlich, Azam Nahvi, Lee J. Helman, Crystal L. Mackall, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi‐Chia Richard Lee, Catherine Lévy, Yong F. Li, Mona El‐Gamil, Susan Schwarz, Carolyn M. Laurençot, Steven A. Rosenberg
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert Somerville, Robert O. Carpenter, Maryalice Stetler‐Stevenson, James C. Yang, Giao Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven A. Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, André Goy, Tatyana Feldman, David Spaner, Michael Wang, Clara C. Chen, Sarah M. Kranick, Avindra Nath, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, Steven A. Rosenberg
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer, Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler‐Stevenson, Steven A. Feldman, Irina Marić, Mark Raffeld, Debbie-Ann N. Nathan, Brock Lanier, Richard A. Morgan, Steven A. Rosenberg
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James Chih‐Hsin Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi‐Chia Richard Lee, Yong F. Li, Mona El‐Gamil, Steven A. Rosenberg